328 related articles for article (PubMed ID: 1613318)
1. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential.
Onundarson PT; Francis CW; Marder VJ
J Lab Clin Med; 1992 Jul; 120(1):120-8. PubMed ID: 1613318
[TBL] [Abstract][Full Text] [Related]
2. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).
Trusen B; Ries M; Zenker M; Rauh M; Beinder E; Keuper H; Harms D
Semin Thromb Hemost; 1998; 24(6):599-604. PubMed ID: 10066156
[TBL] [Abstract][Full Text] [Related]
3. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
Sabovic M; Lijnen HR; Keber D; Collen D
Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
[TBL] [Abstract][Full Text] [Related]
4. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
Watahiki Y; Scully MF; Ellis V; Kakkar VV
Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
[TBL] [Abstract][Full Text] [Related]
5. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
6. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen depletion during streptokinase treatment or two-chain urokinase incubation correlates with decreased clot lysability ex vivo and in vitro.
Onundarson PT; Haraldsson HM; Bergmann L; Francis CW; Marder VJ
Thromb Haemost; 1993 Dec; 70(6):998-1004. PubMed ID: 8165625
[TBL] [Abstract][Full Text] [Related]
9. In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes.
Electricwala A; Ling RJ; Sutton PM; Griffiths B; Riley PA; Atkinson T
Thromb Haemost; 1985 Apr; 53(2):200-3. PubMed ID: 4040659
[TBL] [Abstract][Full Text] [Related]
10. In vitro comparison of fibrinolytic activity of plasminogen activators using a thrombelastographic method: in vivo evaluation of the B-chain-streptokinase complex in the dog model using pre-titered doses.
Summaria L; Sandesara J; Yang G; Vagher JP; Caprini JA
Thromb Haemost; 1986 Aug; 56(1):71-9. PubMed ID: 2946093
[TBL] [Abstract][Full Text] [Related]
11. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
[TBL] [Abstract][Full Text] [Related]
12. Turbulent axially directed flow of plasma containing rt-PA promotes thrombolysis of non-occlusive whole blood clots in vitro.
Tratar G; Blinc A; Strukelj M; Mikac U; Sersa I
Thromb Haemost; 2004 Mar; 91(3):487-96. PubMed ID: 14983224
[TBL] [Abstract][Full Text] [Related]
13. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
[TBL] [Abstract][Full Text] [Related]
14. The effect of 40 kHz ultrasound on tissue plasminogen activator-induced clot lysis in three in vitro models.
Pieters M; Hekkenberg RT; Barrett-Bergshoeff M; Rijken DC
Ultrasound Med Biol; 2004 Nov; 30(11):1545-52. PubMed ID: 15588966
[TBL] [Abstract][Full Text] [Related]
15. Role of alpha 2-antiplasmin in fibrin-specific clot lysis with single-chain urokinase-type plasminogen activator in human plasma.
Declerck PJ; Lijnen HR; Verstreken M; Collen D
Thromb Haemost; 1991 Apr; 65(4):394-8. PubMed ID: 2057921
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen, plasminogen activator, and platelets in the regulation of clot lysis. Reconstitution and patient studies.
Carroll RC; Radcliffe RD; Taylor FB; Gerrard JM
J Lab Clin Med; 1982 Dec; 100(6):986-96. PubMed ID: 6890569
[TBL] [Abstract][Full Text] [Related]
17. Correlation between progressive adsorption of plasminogen to blood clots and their sensitivity to lysis.
Sabovic M; Lijnen HR; Keber D; Collen D
Thromb Haemost; 1990 Nov; 64(3):450-4. PubMed ID: 2096491
[TBL] [Abstract][Full Text] [Related]
18. Influence of intrinsic and extrinsic plasminogen upon the lysis of thrombi in vitro.
Nishino N; Kakkar VV; Scully MF
Thromb Haemost; 1991 Dec; 66(6):672-7. PubMed ID: 1796413
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood.
Haskel EJ; Eisenberg PR; Abendschein DR
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):7-13. PubMed ID: 8457655
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]